Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT01293669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
Targacept Inc. (from the registry)
Registry
  • NCT NCT01293669
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01293669. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TC-6987
Intervention (Drug)
Placebo
Lead sponsor
Targacept Inc. (class: industry)

Record details

Record id
cardio:ct-nct01293669
Content hash
2b872a10a9231e97097e391a6fb62037a58e1d71c7f54883c31a8c4079c29779